MAPs are increasingly used to provide patients with serious or life-threatening conditions access to medicines before full regulatory approval.

Yet for many supply chain professionals, MAPs remain poorly understood — often seen as “medical” or “regulatory” initiatives, rather than programs with significant supply, quality, and operational implications.